Sequenom (SQNM) Gets Rights to Develop and Commercialize to Predict Genetic Predisposition for Macular AMD
Tweet Send to a Friend
Sequenom, Inc. (NASDAQ: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
